<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172156</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO1018</org_study_id>
    <nct_id>NCT03172156</nct_id>
  </id_info>
  <brief_title>ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS</brief_title>
  <official_title>Multicentre, Prospective, Open Clinical Study of Postoperative ctDNA Dynamic Monitoring and Its Role of Prognosis in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CtDNA detection is a noninvasive detection method, and the second generation of
      high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can
      detect trace ctDNA from smaller plasma samples. This project is to study the role of ctDNA
      dynamic monitoring of stage I NSCLC by NGS technique to verify the prognostic predictive
      effect of ctDNA .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CtDNA detection as a noninvasive detection method, can truly reflect the real tumor tissue
      gene mutation map and frequency, is the evaluation of therapeutic effect and the important
      monitoring indicators of clinical follow-up after treatment. The second generation of
      high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can
      detect trace ctDNA from smaller plasma samples. The ctDNA dynamic monitoring of stage I
      non-small cell lung cancer (NSCLC) was performed by the second generation gene sequencing
      (NGS) technique to verify the prognostic predictive effect of ctDNA in stage I NSCLC patients
      without radiotherapy and targeted therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years after the last patient enrolled</time_frame>
    <description>Disease-free survival was assessed from surgery to disease recurrence or death as a result of any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after the last patient enrolled</time_frame>
    <description>Overall survival was assessed from surgery to death as a result of any cause</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer Stage I</condition>
  <arm_group>
    <arm_group_label>Stage I NSCLC patients after surgery with ctDNA detection</arm_group_label>
    <description>Stage I NSCLC patients;ctDNA detection</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ctDNA detection</intervention_name>
    <description>To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)</description>
    <arm_group_label>Stage I NSCLC patients after surgery with ctDNA detection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      ctDNA of stage I non-small cell lung cancer (NSCLC)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With Stage I Non-small Cell Lung Cancer (NSCLC) without Postoperative radiotherapy
        and chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postoperative histopathological diagnosis of TNM stage IA / IB NSCLC with R0
             resection;

          -  No adjuvant chemotherapy, radiotherapy, targeted drug therapy or biotherapy after
             surgery;

        General selection criteria:

          -  Men or women of age â‰¥18 years and &lt;75 years old;

          -  ECOG behavior status score 0 to 1;

        Exclusion Criteria:

          -  Patients with other cancers other than NSCLC within five years prior to this study;

          -  who can not get enough tumor histological specimens (non-cytological) for analysis;

          -  human immunodeficiency virus (HIV) infection;

          -  NSCLC mixed with patients with small cell lung cancer;

          -  pregnant or lactating women;

          -  There is a clear history of neurological or mental disorders, including epilepsy or
             dementia;

          -  Conditions that investigators think is not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Si-Yu Wang, MD</last_name>
    <phone>86-20-87343439</phone>
    <email>wsysums@163.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhenguo liu, MD</last_name>
    <phone>86-20-87755766</phone>
    <phone_ext>8782</phone_ext>
    <email>liuzg1340@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Si-Yu Wang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chao cheng, MD</last_name>
      <phone>+86-20-87755766</phone>
      <phone_ext>8782</phone_ext>
      <email>drchengchao@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhenguo Liu, MD</last_name>
      <phone>+86-20-87755766</phone>
      <phone_ext>8782</phone_ext>
      <email>liuzg1340@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Si-Yu Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenguo Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Si-Yu Wang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>stage I</keyword>
  <keyword>The next generation of high-throughput gene sequencing (NGS)</keyword>
  <keyword>ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The investigators will not share IPD to other researchers until initial experimental conclusions is reached.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

